Japan Tissue Engineering Co., Ltd. (7774.T)
Tokyo · JPY · Healthcare · Biotechnology
¥741 (+1.51%) as of
Key statistics
- Market cap
- 30.09B
- Forward P/E
- 51.10
- EPS (TTM)
- -10.83
- Dividend yield
- 0.00%
- 52-week range
- 448.00 – 927.00
- Beta
- 0.64
- Revenue (TTM)
- 2.52B
- Profit margin
- -17.44%
- Volume
- 79.30k
About Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Contract, and Lab Site Project segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it offers EPI-MODEL, a reconstructed human epidermis model. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. operates as a subsidiary of Teijin Limited.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Gamagori, Japan
- Employees
- 200
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.